NTNicola Tufton

Nicola Tufton

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nicola Tufton has a total of 70 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The immune cell infiltrate in the tumour microenvironment of phaeochromocytomas and paragangliomas

    by Nicola Tufton, Robert J Hearnden, Daniel M Berney, William M Drake, Laila Parvanta, J Paul Chapple, Scott A Akker

    Emerging evidence suggests the composition of the tumour microenvironment (TME) correlates with clinical outcome and that each tumour type has a unique TME including a variable population of inflammatory cells. We performed immunohistochemistry on 65 phaeochromocytoma and paraganglioma (PPGL) tumour samples with 20 normal adrenal medulla samples for comparison. The immune cells assessed were macrophages, lymphocytes and neutrophils and we compared the proportion of infiltration of these immune cells with clinical and histopathological factors. There was a higher proportion of immune cells in tumour tissue compared to non-neoplastic adrenal medulla tissue, with a predominance of macrophages. There was a higher proportion of M2:M1 macrophages and T helper lymphocytes in aggressive tumours compared to indolent ones. For SDHB associated tumours there was a higher proportion M2 macrophage infiltration, with higher M2:M1 in aggressive SDHB PPGLs compared to indolent tumours. These data demonstrate that immune cells do infiltrate the TME of PPGLs, confirming that PPGLs are immunologically active tumours. Differences in the TME of PPGLs were observed between aggressive and indolent tumours. These differences could potentially be exploited as an aid to predicting tumour behaviour.


  • Open Access

    Investigating the role of somatic sequencing platforms for phaeochromocytoma and paraganglioma in a large UK cohort

    by Bettina Winzeler, Nicola Tufton, Eugenie S. Lim, Ben G. Challis, Soo‐Mi Park, Louise Izatt, Paul V. Carroll, Anand Velusamy, Tony Hulse, Benjamin C. Whitelaw, et al.

    Objectives Phaeochromocytomas and paragangliomas (PPGL) are rare neuroendocrine tumours with malignant potential and a hereditary basis in almost 40% of patients. Germline genetic testing has transformed the management of PPGL enabling stratification of surveillance approaches, earlier diagnosis and predictive testing of at-risk family members. Recent studies have identified somatic mutations in a further subset of patients, indicating that molecular drivers at either a germline or tumour level can be identified in up to 80% of PPGL cases. The aim of this study was to investigate the clinical utility of somatic sequencing in a large cohort of patients with PPGL in the United Kingdom. Design and Patients Prospectively collected matched germline and tumour samples (development cohort) and retrospectively collected tumour samples (validation cohort) of patients with PPGL were investigated. Measurements Clinical characteristics of patients were assessed and tumour and germline DNA was analysed using a next-generation sequencing strategy. A screen for variants within ‘mutation hotspots’ in 68 human cancer genes was performed. Results Of 141 included patients, 45 (32%) had a germline mutation. In 37 (26%) patients one or more driver somatic variants were identified including 26 likely pathogenic or pathogenic variants and 19 variants of uncertain significance. Pathogenic somatic variants, observed in 25 (18%) patients, were most commonly identified in the VHL, NF1, HRAS and RET genes. Pathogenic somatic variants were almost exclusively identified in patients without a germline mutation (all but one), suggesting that somatic sequencing is likely to be most informative for those patients with negative germline genetic test results. Conclusions Somatic sequencing may further stratify surveillance approaches for patients without a germline genetic driver and may also inform targeted therapeutic strategies for patients with metastatic disease.


  • SDHC phaeochromocytoma and paraganglioma: A UK‐wide case series

    by Sophie T. Williams, Prodromos Chatzikyriakou, Paul V. Carroll, Barbara M. McGowan, Anand Velusamy, Gemma White, Rupert Obholzer, Scott Akker, Nicola Tufton, Ruth T. Casey, et al.

    Objective: Phaeochromocytomas and paragangliomas (PPGL) are rare, but strongly heritable tumours. Variants in succinate dehydrogenase (SDH) subunits are identified in approximately 25% of cases. However, clinical and genetic information of patients with SDHC variants are underreported.Design: This retrospective case series collated data from 18 UK Genetics and Endocrinology departments.Patients: Both asymptomatic and disease‐affected patients with confirmed SDHC germline variants are included.Measurements: Clinical data including tumour type and location, surveillance outcomes and interventions, SDHC genetic variant assessment, interpretation, and tumour risk calculation.Results: We report 91 SDHC cases, 46 probands and 45 non‐probands. Fifty‐one cases were disease‐affected. Median age at genetic diagnosis was 43 years (range: 11–79). Twenty‐four SDHC germline variants were identified including six novel variants. Head and neck paraganglioma (HNPGL, n = 30, 65.2%), extra‐adrenal paraganglioma (EAPGL, n = 13, 28.2%) and phaeochromocytomas (PCC) (n = 3, 6.5%) were present. One case had multiple PPGLs. Malignant disease was reported in 19.6% (9/46). Eight cases had non‐PPGL SDHC‐associated tumours, six gastrointestinal stromal tumours (GIST) and two renal cell cancers (RCC). Cumulative tumour risk (95% CI) at age 60 years was 0.94 (CI: 0.79–0.99) in probands, and 0.16 (CI: 0–0.31) in non‐probands, respectively.Conclusions: This study describes the largest cohort of 91 SDHC patients worldwide. We confirm disease‐affected SDHC variant cases develop isolated HNPGL disease in nearly 2/3 of patients, EAPGL and PCC in 1/3, with an increased risk of GIST and RCC. One fifth developed malignant disease, requiring comprehensive lifelong tumour screening and surveillance.


  • Diffusion‐weighted imaging (DWI) highlights SDHB‐related tumours: A pilot study

    by Nicola Tufton, Gemma White, William M. Drake, Anju Sahdev, Scott A. Akker

    Objective There is consensus that asymptomatic carriers of SDHB mutations should undergo periodic surveillance imaging. MRI has the advantage of avoiding radiation exposure but its sensitivity and specificity for detecting phaeochromocytoma and paraganglioma (PPGL) is dependent on sequences performed and expertise of reporting radiologists. We aim to highlight the additional value of Diffusion‐weighted imaging (DWI) for MR based surveillance, demonstrating DWI's ability to identify small PPGLs at all body sites. Design We presented DWI sequences taken as part of SDHB surveillance to a radiologist, expert in reporting PPGL screening scans. Areas of high signal on DWI were interrogated using other standard MRI sequences. Patients We reviewed the MRI scans for 18 SDHB mutation carriers with a total of 18 histologically proven SDHB‐related tumours and 12 presumed PGLs/metastatic deposits. Results The DWI sequences identified all 30 lesions. False positive lesions were excluded by standard sequences. The tumours detected by DWI ranged in size from 5‐52mm. PPGLs were identified on DWI in the abdomen (n=14), adrenal gland (n=1), thorax (n=3), neck (n=2), and bladder (n=2). Additionally other SDHB‐related tumours (GIST, RCC) were also highlighted by DWI, as were metastatic deposits in the liver and bone. Conclusions These preliminary data suggest that DWI has high sensitivity and can identify even small SDHB‐related tumours. If these findings are confirmed in larger series, for all SDH subunits, it will provide reassurance about identifying small SDH‐related tumours, without exposing patients to the consequences of radiation‐based imaging and will secure the role of MRI for surveillance imaging.


  • Can subunit‐specific phenotypes guide surveillance imaging decisions in asymptomatic SDH mutation carriers?

    by Nicola Tufton, Anju Sahdev, William M. Drake, Scott A. Akker

    Summary: Objective: With the discovery that familial phaeochromocytoma and paraganglioma syndrome can be caused by mutations in each subunit of the succinate dehydrogenase enzyme (SDH), has come the recognition that mutations in the individual subunits have their own distinct natural histories. Increased genetic screening is leading to the identification of increasing numbers of, mostly asymptomatic, gene mutation carriers and the implementation of screening strategies for these individuals. Yet there is, to date, no international consensus regarding screening strategies for asymptomatic carriers.Design: A comprehensive PubMed search from 1/1/2000 to 28/2/2018 was undertaken using multiple search terms and subsequently a manual review of references in identified papers to identify all clinically relevant cases and cohorts. In this review, the accumulated, published experience of phenotype and malignancy risks of individual SDH subunits is analysed. Where possible screening results for asymptomatic SDH mutation carriers have been analysed separately to define the penetrance in asymptomatic carriers (asymptomatic penetrance).Results: The combined data confirms that “asymptomatic penetrance” is highest for SDHD and when there is penetrance, the most likely site to develop a PGL is head and neck (SDHD) and extra‐adrenal abdominal (SDHB). However, the risk in SDHB carriers of developing HNPGL is also high (35.5%) and a PCC is low (15.1%), and in SDHD carriers there is a high risk of developing a PCC (35.8%) or abdominal PGL (9.4%) and a small, but significant risk at other sympathetic sites. The data suggest that the risk of malignant transformation is the same for both PCC and extra‐adrenal abdominal PGLs (30%‐35%) in SDHB carriers. In SDHD carriers, the risk of malignant transformation was highest in HNPGLs (7.5%) and similar for sympathetic sites (3.8%‐5.2%).Conclusions: Using this data, we suggest surveillance screening of asymptomatic carriers can be tailored to the underlying SDH subunit and review possible surveillance programmes.


  • Eponymous mischief: A syndrome within a syndrome

    by Nicola Tufton, Susan Cross, Scott Akker

    Case history: A 32 year old male diagnosed with McCune-Albright syndrome aged 18, presented with a painful left knee and difficulty in walking, limiting his usual activities. He was diagnosed with Acromegaly (IGF-1 451 ng/ml, mean GH 2.71 ug/L) aged 26 years and had multiple sites of fibrous dysplasia, causing bone pain. On examination he had tall stature and features of acromegaly with normal visual fields and palpable masses behind his left knee and upper thigh. Investigations: ALP 657 u/l, ALT 42 u/l, bilirubin 31 umol/l, cCa 2.3 mmol/l, PO4 0.77 mmol/l, vitamin D 69 nmol/l, FT4 15.5 pmol/l, TSH 1.95 mu/l, IGF-1 365 mcg/l (82.5–240.4 mcg/l), mean GH 2.078 ug/l, serum procollagen type 1 amino terminal peptide (P1NP) 1158 ug/L (ref range 20–76), FGF23 160 RU/mL (ref range <100). MRI head demonstrated a normal size pituitary gland, without an obvious focal lesion, but with extensive fibrous dysplasia of the skull vault and facial bones. A whole body bone can confirmed diffuse intense tracer uptake throughout the skeleton, which showed stability in fibrous dysplasia from a scan 3 years previously. MRI demonstrated polyostotic fibrous dysplasia and multiple lobulated intramuscular soft tissue masses, with heterogeneous enhancement, the largest of which measured 6×9×10 cm. Treatment: Pituitary surgery was relatively contraindicated due to the extensive facial and skull bone disease making access difficult. He was therefore treated with monthly Sandostatin injections, but was not very compliant with this treatment, due to gastrointestinal side effects. He received bisphosphate infusions for his bone disease. Discussion: McCune-Albright syndrome is a rare condition that remains difficult to diagnose and manage, due to the multiple endocrine and bone complications. There is a rare association between McCune Albright syndrome and multiple myxomas known as Mazabraud syndrome. The first case was described in 1967, but very few cases have been reported in the literature. It is more common in women and tends to affect the larger lower limb muscle groups. Its occurrence in men is extremely rare, and myxomas tend to occur before the onset of fibrous dysplasia. There is an association between Mazabraud syndrome and an increased risk of sarcoma in the underlying bone, although the myxomas themselves do not seem to have an inherent malignancy risk. Use of new biochemical tests confirmed poor compliance with medications and high bone turnover. We will discuss the difficulties and management options posed by this case.

  • A pressing diagnosis in an adolescent

    by Sam O'Toole, Nicola Tufton, Lorena Arnez, Laila Parvanta, Scott Akker

    Case history: A 17 year old previously healthy male presented to his local emergency department with a generalised tonic seizure associated with severe hypertension (systolic blood pressure 240 mmHg) and tachycardia. He was intubated and admitted to the Intensive Care Unit. Antimicrobials to cover meningoencephalitis were commenced and his hypertension was managed with intravenous labetalol. He was extubated the following day. He had experienced headaches on a monthly basis for two years. They had become more severe and frequent in the weeks prior to presentation and were associated with paroxysms of sweating and palpitations. There was no suggestive family history. A 24 h urine collection was sent for metanephrines, however, given the significant suspicion of a phaeochromocytoma, he was commenced on phenoxybenzamine and abdominal imaging was undertaken prior to diagnostic biochemistry becoming available. He was subsequently transferred to our centre for ongoing investigation and management. Results and treatment: Initial blood tests demonstrated haemoconcentration with an acute kidney injury and active urinary sediment. CT and MRI demonstrated cerebral oedema within the occipital lobes and brainstem consistent with a diagnosis of posterior reversible encephalopathy syndrome (PRES). Urine normetanephrine was significantly elevated with a normal metanephrine and 3-methoxytyramine. The magnitude of normetanephrine elevation was significantly higher at presentation (×8.8 upper limit of normal) compared to on transfer (×2.4). Abdominal imaging demonstrated a 4.1 cm left phaeochromocytoma that was invading the renal vein. This lesion was MIBG-avid. Two small indeterminate pulmonary nodules were identified on thoracic imaging. Low molecular weight heparin was commenced in light of tumour thrombus in the renal vein. Phenoxybenzamine dose was uptitrated and propranolol subsequently added. After a number of weeks of outpatient blockade he underwent an open adrenalectomy and nephrectomy. His post-operative course was complicated by pneumonia and wound discharge. Anti-hypertensives were successfully discontinued post-operatively. Histology confirmed the diagnosis of a phaeochromocytoma, which was completely excised. Immunohistochemistry for the SDHB protein was negative, highly suggestive of a germline mutation in an SDHx gene and confirmation of this is awaited. Conclusions and points for discussion: This case of a locally invasive phaeochromocytoma in an adolescent who presented with PRES provides an excellent opportunity to discuss: • The acute management of a phaeochromocytoma crisis (particularly given the discontinuation of intravenous phenoxybenzamine) • How pre-operative suspicion of a germline predisposition to phaeochromocytoma development might influence imaging and surgical strategy • Optimal surveillance strategy for this patient in particular and those with confirmed SDHx mutations generally

  • An unexpected VIP

    by Niki Margari, Nicola Tufton, Karunakaran Vithian, Sampi Mehta, Scott Akker

    Case history: A 69-year-old Caucasian male presented with persistent abdominal pain and was found to have a large right adrenal mass on CT. Interestingly his family history revealed that his daughter had been treated for Cushing’s disease. He was normotensive and denied classical symptoms of catecholamine excess. He had exertional dyspnoea in keeping with COPD. Subsequent tests were consistent with a secretory phaeochromocytoma and urine normetadrenaline 85,671 nmol/day (<4,400 nmol/day), metadrenaline 39,110 nmol/day (<2,00 nmol/day) and 3-methoxytyramine 3,154 nmol/day (<2,500 nmol/day). He was commenced on alpha- and beta-blockade. Whilst on holiday, prior to surgery, he collapsed with abdominal pain and developed severe watery diarrhoea. Investigations: Blood tests on admission to A/E revealed acute renal failure with profound hypokalaemia. Stool samples tested negative for bacterial and parasitic infections but the life-threatening high volume diarrhoea continued, requiring large volumes of fluid resuscitation. A repeat CT abdomen was in keeping with new central necrosis. Results and treatment: The patient was transferred, due to the difficult to manage severe diarrhoea and for consideration of an octreotide infusion. After 10 days and significant weight loss, the diarrhoea started to abate and five weeks later he underwent an open right adrenalectomy with an uneventful recovery period. Results received post-operatively revealed that his fasting gut peptides on transfer showed vasoactive intestinal peptide (VIP) levels of 300 pmol/l (<30). Subsequent post-operative fasting VIP levels were undetectable. Histology confirmed a phaeochromocytoma with a Ki-67 of up to 20% and SDHB immunohistochemistry was normally expressed. Points for discussion: We present a rare complication, which we attribute to the partial infarction of a large secretory phaeochromocytoma. We will discuss the propensity of large phaeochromocytomas to undergo infarction or bleeding, which in turn can lead to a crisis. In this case the alpha and beta- blockade partially protected the patient from the catecholamine surge but the unexpected release of VIP was life threatening in itself. The timing of surgery for phaeochromocytomas remains a difficult clinical balance weighing up the benefits of a period of blockade versus the potential risks of having a ‘blocked’ phaeochromocytoma in situ. The fact that many phaeochromocytomas make other peptides adds to the uncertainty and we will discuss the peptides that can contribute to these management difficulties.

  • Open Access

    Excluding the pheochromocytoma

    by Nicola Tufton, Scott A. Akker


  • Open Access

    Pituitary Carcinoma in a Patient with an SDHB Mutation

    by Nicola Tufton, Federico Roncaroli, Irene Hadjidemetriou, Mary N Dang, Judit Dénes, Leonardo Guasti, Maria Thom, Michael Powell, Stephanie E Baldeweg, Naomi Fersht, et al.

    We present the first case of pituitary carcinoma occurring in a patient with a succinate dehydrogenase subunit B (SDHB) mutation and history of paraganglioma. She was initially treated for a glomus tumour with external beam radiotherapy. Twenty-five years later, she was diagnosed with a non-functioning pituitary adenoma, having developed bitemporal hemianopia. Recurrence of the pituitary lesion (Ki-67 10% and p53 overexpressed) occurred 5 years after her transsphenoidal surgery, for which she underwent two further operations followed by radiotherapy. Histology showed large cells with vacuolated clear cytoplasm with positive immunostaining for steroidogenic factor 1 (SF1) and negative staining for pituitary hormones. Four years after the pituitary radiotherapy, two metastatic deposits were identified: a foramen magnum lesion and an intradural extra-medullary cervical lesion at the level of C3/C4. There was also significant growth of the primary pituitary lesion with associated visual deterioration. A biopsy of the foramen magnum lesion, demonstrating cells with vacuolated, clear cytoplasm and positive SF1 staining confirmed a pituitary carcinoma, for which she was commenced on temozolomide chemotherapy. There was dramatic clinical improvement after three cycles and reduction in the size of the lesions was observed following six cycles of temozolomide, and further shrinkage after 10 cycles. The plan is for a total of 12 cycles of temozolomide chemotherapy. SDH mutation-related pituitary tumours have an aggressive phenotype which, in this case, led to metastatic disease. SF1 immunostaining was helpful to identify the tissue origin of the metastatic deposit and to confirm the pituitary carcinoma.